StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Inhibrx Biosciences's operating cash flow for the twelve months ending Sep 30, 2026 was -$132.67M. For fiscal 2025 it was -$129.79M. The highest annual figure on record is -$32.08M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$129.79M–
FY2024Dec 31, 2024-$194.41M–
FY2023Dec 31, 2023-$193.31M–
FY2022Dec 31, 2022-$115.30M–
FY2021Dec 31, 2021-$80.32M–
FY2020Dec 31, 2020-$47.97M–
FY2019Dec 31, 2019-$32.08M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$34.61M–
Q2 FY2026Jun 30, 2026-$29.92M–
Q1 FY2026Mar 31, 2026-$38.03M–
Q4 FY2025Dec 31, 2025-$30.12M–
Q3 FY2025Sep 30, 2025-$33.82M–
Q2 FY2025Jun 30, 2025-$29.95M–
Q1 FY2025Mar 31, 2025-$35.90M–
Q4 FY2024Dec 31, 2024-$43.72M–
Q3 FY2024Sep 30, 2024-$30.28M–
Q2 FY2024Jun 30, 2024-$57.36M–
Q1 FY2024Mar 31, 2024-$63.05M–
Q4 FY2023Dec 31, 2023-$56.82M–
Q3 FY2023Sep 30, 2023-$54.25M–
Q2 FY2023Jun 30, 2023-$42.30M–
Q1 FY2023Mar 31, 2023-$39.94M–
Q4 FY2022Dec 31, 2022-$30.60M–
Q3 FY2022Sep 30, 2022-$30.84M–
Q2 FY2022Jun 30, 2022-$26.92M–
Q1 FY2022Mar 31, 2022-$26.94M–
Q4 FY2021Dec 31, 2021-$22.62M–
Q3 FY2021Sep 30, 2021-$13.68M–
Q2 FY2021Jun 30, 2021-$22.38M–
Q1 FY2021Mar 31, 2021-$21.65M–
Q4 FY2020Dec 31, 2020-$15.39M–
Q3 FY2020Sep 30, 2020-$13.88M–
Q2 FY2020Jun 30, 2020-$11.31M–
Q1 FY2020Mar 31, 2020-$7.39M–
Q4 FY2019Dec 31, 2019-$11.94M–

More Inhibrx Biosciences figures

See a number that looks wrong?